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Chronic inflammation is a major biological mechanism underpinning biological ageing process and age-related
diseases. Inflammation is also the key response of host defense against pathogens and tissue injury. Current opinion
sustains that during evolution the host defense and ageing process have become linked together. Thus, the large
array of defense factors and mechanisms linked to the NF-κB system seem to be involved in ageing process. This
concept leads us in proposing inductors of NF-κB signaling pathway as potential ageing biomarkers. On the other
hand, ageing biomarkers, represented by biological indicators and selected through apposite criteria, should help to
characterize biological age and, since age is a major risk factor in many degenerative diseases, could be
subsequently used to identify individuals at high risk of developing age-associated diseases or disabilities. In this
report, some inflammatory biomarkers will be discussed for a better understanding of the concept of biological
ageing, providing ideas on eventual working hypothesis about potential targets for the development of new
therapeutic strategies and improving, as consequence, the quality of life of elderly population.
Keywords: Biological ageing process, Inflammatory network and its effects in ageing, NF-κB signaling pathway as
hub of inflammatory ageing network, Inflammatory biomarkersIntroduction
Ageing is a complex process, induced by an intricate
interaction of genetic, epigenetic, stochastic and envir-
onmental factors. They determine the lost of molecular
fidelity followed by an improved entropy [1,2]. As result,
loss complexity and random accumulation of damages (i.e.
particularly damages to nuclear and mitochondrial DNA)
at cellular, tissue, organ levels and/or of whole body arise,
compatibly with the disposable soma theory of ageing [3].
Thus, it establishes a condition, which modifies both
architecture and functioning of physiological processes
and regulatory (immune and endocrine) systems. This de-
termines a deterioration of the homeostasis. Accordingly,
it becomes more easily vulnerable to internal and external
stressors, frailty, disability and disease (Figure 1). On the
other hand, the loss of DNA integrity, the principal ran-
dom damages able in modifying cellular fidelity and indu-
cing cellular and whole body senescence, determines the
decline of the functionality of stress resistance and survival
pathways (i.e. autophagic uptake mechanisms, chaperone* Correspondence: carmelarita.balistreri@unipa.it
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reproduction in any medium, provided the orsystems, DNA repair mechanisms, apoptotic process,
immune/inflammatory response), involved in cellular and
organism defense to environmental stress and maintaining
homeostasis [2]. However, a large heterogeneity in occur-
rence, complications, speed, and age and gender manifest-
ation of ageing process at cellular, tissue, organ levels and/
or of whole body has been observed in humans. Among
human people, there are individuals at the age ≥90 years
still in good mental and physical conditions, and others
that at the age ≥ 60 years show cognitive difficulties, and/
or the onset of chronic inflammatory diseases, such as
Alzheimer’s disease (AD), cardiovascular disease (CVD)
and type 2 diabetes mellitus (T2DM) and cancer [4].
The principal causes of the heterogeneity in human
ageing rate, measured as decline of functional capacity
and stress resistance, seem to be genetic and environ-
mental factors. However, the overall impression is that
environmental factors are the major determinants of
both ageing and age-related diseases [4,5]. Thus, ageing
process is not a genetically programmed process [5].
This consideration is based on studies on heritability of
age-related diseases and ageing [6,7]. A similar value of
heritability in lifespan and age-related diseases, such asl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Ageing process results by the lost of molecular fidelity followed by an improved entropy. This determines loss complexity and
random accumulation of damages (i.e. particularly damages to nuclear and mitochondrial DNA) at cellular, tissue, organ levels and/or of whole
body. Thus, it becomes more easily vulnerable to internal and external stressors, frailty, disability and disease.
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vs. 40%, respectively) [8,9]. However, this does not imply
that genetic factors have an irrelevant role in ageing and
age-related diseases. For example, mutations identified
in familial forms of AD consented understanding its mo-
lecular mechanisms, such as the toxicity of amyloid β
peptide and potential therapeutic targets in more com-
mon sporadic late onset AD [10]. Common suggestion is
based on both a complex contribution of genetic factors
in ageing and diseases of later life and weak effects of in-
dividual genes [5]. Furthermore, diverse genetic factors
are associated with ageing and exceptional longevity.
Human genome-wide genetic analyses have revealed
only few age-related loci and polymorphic longevity
genes [11-13]. Among these, current promising candi-
dates are Sirtuins, Forkhead box O protein (FoxOs) and
the field of epigenetics. Functional genomics, i.e. expres-
sion profiling studies, have revealed a group of genes
which are differently expressed in ageing, such as
immune/inflammatory genes [14].
From the observations described above, another crit-
ical point of ageing process emerges based on the con-
cept of biological age as real expression in human of
both ageing rate and onset of the common diseases of
later life rather than chronological age [15]. This concept
opened an important area of research focused on identi-
fying of potential molecular targets as biomarkers ofhuman biological ageing [16]. On the one hand, it could
consent to develop potential anti-ageing treatment strat-
egies. On the other hand, probable anti-ageing treat-
ments could retard or prevent age-associated diseases
resulting in widespread health, social and economic
benefit. Such treatment could include genetic engineer-
ing, such as gene therapy or endogenous gene repair, or
pharmacological therapies, or changes in lifestyle, i.e.
physical activity, diet.
In this report, many of these aspects are discussed,
giving particular emphasis in describing some bio-
markers of inflammation. In particular, the data dis-
cussed in this report are based on an expert opinion
derived on the findings from author’s studies on ageing,
age-related diseases and inflammation.
Definition and selection criteria of ageing biomarkers
As established by National Institute of Health, a bio-
marker is a “feature objectively measured and evaluated
as an indicator of normal biologic processes, pathogenic
processes, or pharmacologic responses to a therapeutic
intervention” [16,17].
In the case of ageing process, this definition might
concern measures related to physical changes, such as
grey hairs, reduced skin elasticity, wrinkles, reduced
muscle strength or changes in the near vision, which are
thought to be the result of molecular mechanisms
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chronological age rather than the biological age, which
is the most important indicator of health and potential
lifespan [15].
A biomarker of real ageing should reflect a process of
biological ageing, be easily reproducible in cross-species
comparison, be easily obtainable. Since ageing is the re-
sult of the deterioration of more than one system or
process, it would be more appropriate to consider differ-
ent biomarkers. Panels of biomarkers associated with
conditions, alterations or changes of a set of critical sys-
tems to assess the biological age of any organism should
be used [16,18].
The gerontologists have begun to face this problem
already in the early 1980s, with the development of a
large number of ageing biomarkers [16,18]. Despite the
numerous efforts and the support in this research from
National Institute of Ageing, the major number of bio-
markers is still to date under discussion, like inflamma-
tory markers, hormones, markers of oxidative stress or
telomere shortening [16,18]. Most (perhaps all) markers
are also not really proven in longitudinal studies in
humans. In addition, they have been considered for a
variety of purposes, which are not distinguished suffi-
ciently. Most studies used biomarkers as tools for com-
paring ageing rate in several populations or cohorts of a
single population. In contrast, others considered bio-
markers for person-specific predisposition, which repre-
sents much more challenging, principally because
ageing, as a biological process, is not well defined at in-
dividual level. In addition, the research of comparative
or predictive biomarkers have determined the attempted
use of measure panels associated with survival, health
of old age, frailty, age-related (multi) morbidity and
mortality [16,18].
However, none of the identified biomarkers is a “real”
biomarkers of ageing. They are commonly related to age
and diseases. In addition, the major number has been
developed and tested for diseases in which biological age
is the single biggest risk factor, such as peripheral blood
cellular telomere length, indicators of immuno-
senescence, even without correlations with disease-
specific diagnoses. In addition, biomarkers of age-related
diseases and ageing have been preferentially identified in
younger-old populations (typically aged 60–85), but notTable 1 Criteria for a biomarker of ageing process
I It must predict the rate of ageing. In other words, it would estimate
predictor of lifespan than chronological age alone.
II It must monitor a basic process that underlines the ageing process, n
III It must be able to be tested repeatedly without harming the person
IV It must be something that works in humans and in laboratory anima
before being validated in humans.in oldest-old (aged 85 and above) [16,18]. For example,
blood pressure, indicators of metabolic syndrome and
telomere length do not associate significantly with age-
related morbidity or mortality in population-based stud-
ies of the oldest-old [19-21]. Thus, biomarkers of ageing
and age-related diseases in understanding the health tra-
jectories of the oldest-old are unexplored. It is import-
ant that this lacuna is filled given the rapid growth in
the number of very old people in many contemporary
populations.
For an ageing biomarker, it is important to know not
only its definition, but also the criteria for its selection.
Accordingly, the American Federation for Ageing Re-
search suggested detailed criteria, recently reviewed by
Sprott [16] and Johnson [18]. Based on these criteria, a
true biomarker of ageing, in order to be both accurate
and useful, should predict a person’s physiological, cog-
nitive and physical function in an age-related way. In the
same time, it should be easily testable, and not harmful
to test individuals. For example, it could be a blood test
or an image technique, by performing accurately and re-
producibly without the need for specialized equipment
or techniques. It should be tested preliminary in labora-
tory animals, such as mice, and successively in humans.
Thus, a biomarker needs to be simple and inexpensive
to use. They should cause little or no pain and stress
(see Table 1) [16,18].
Furthermore, current research on ageing biomarkers is
also focusing in identifying molecules which also are
able in giving clinical indications. On the other hand,
biomarkers represent a hot topic and have the ability to
change our life, if real prediction, on an individual basis,
can be made in the future.
Description and ageing biological effects of inflammatory
network
Immune system is evolved to defend the host against
microbial invasion, and to counteract tissue damage elic-
ited by chemical or physical agents or trauma,
maintaining consequently the homeostasis and tissue re-
pair [22]. In both conditions, it responds in a appropri-
ate manner by inducing apposite reactions (i.e. of
suitable degree, with the involvement of a different array
of cells and mediators), called inflammatory responses
[22,23]. Inflammatory responses can be evocated initiallywhere a person is in their total lifespan. Operationally, it must be a better
ot the effects of diseases.
, for example, a blood test or an imaging techniques.
ls, such as mice. This is so that it can be tested in laboratory animals
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phase reaction, represented by systemic cytokine-induced
reactions, including leukocytosis, fever, somnolence, an-
orexia, activation of hypothalamic-pituitary-adrenal axis
and increased level of glucocorticoids, and acute phase
synthesis, i.e. C reactive protein (CRP), in the liver. A
complex network of molecules (the mediators) and cells
(neutrophils, monocytes, mast cells, endothelial cells, etc.)
characterize these reactions. They work together in con-
cert and interact mediating the activation of different sig-
naling pathways and the expression and transcriptional
regulation of hub genes. The hub genes receive and direct
the activity of many other genes [22,23]. Thus, these re-
sponses are induced through an inflammatory network.
Recent studies on topology of this network evidence the
crucial role of some mediators in driving the different cel-
lular interactions and regulating the type of inflammatory
reaction. Several mediators as pro- and anti-inflammatory
molecules are involved [24]. Their release is modulated by
different factors linked to well-known Nuclear Factor
(NF)-κB pathway [25,26]. In addition, the magnitude of
their production varies individually because of genetic het-
erogeneity. Single nucleotide polymorphisms (SNPs) in
several genes and epigenetic factors seem to be involved
[27]. Among the inflammatory mediators, the classical
pro-inflammatory cytokines, Tumor necrosis factor α
(TNF-α), Interleukin-1 (IL-1) and IL-6, play a key role.
They are able in inducing both local and systemic effects
[28]. When the causes of the inflammatory reaction are of
a high intensity, their production is increased. Thus, they
are released in the circulation provoking the acute phase
response. In contrast, the anti-inflammatory cytokines,
such as IL-10 are able to regulate the activation of in-
flammatory cells, by inhibiting the release of pro-
inflammatory cytokines and therefore turning off the
inflammatory processes [29].
Whether tissue health is not restored or in response to
stable low grade irritation, inflammation becomes a
chronic condition provoking continuous damages in the
surrounding tissues. The collateral damage caused by
this type of inflammation usually accumulates slowly,
sometimes asymptomatically for years but can eventually
lead to severe tissue deterioration [30].
From the above, it emerges that the inflammatory re-
sponse is not per se a negative phenomenon. It is pro-
grammed by the evolution in neutralizing infectious
agents, playing a beneficial role until the time of
reproduction and parental care. In contrast, in old age, in
a period largely not foreseen by evolution, it can deter-
mine a detrimental effect through chronic inflammatory
responses (“antagonistic pleiotropy”) in several/ all tissue
and organs, which are cause of both the ageing phenotype
and chronic diseases [24,30]. A low chronic grade of in-
flammation, the “inflammageing”, characterized by a 2 to4-fold increase in serum levels of inflammatory mediators
has been identified in ageing [31]. It seems to be as opti-
mal predictor of mortality and, as mentioned above, a crit-
ical risk factor in the pathogenesis of several age-related
chronic diseases as AD, CVD, T2DM, sarcopenia, frailty
and functional disability [32].
Augment of age-related body fat and consequent in-
crease of visceral adiposity, age-related decline of sex
hormones, oxidative and genotoxic stress, cellular and
tissue damage, nutrition, alterations of physical condi-
tion of gut microbiota, other organs (brain, liver) and
systems (immune and endocrine) have been associated
with inflamm-ageing [32-34]. In addition, factors linking
to physiological stress, such a long-term smoking and
depression, seem also to contribute to inflammageing
[32-34]. However, the most important factor for age-
related inflammation is the long-life pathogen burden
[30]. Some recent studies have, indeed, evidenced associ-
ations between past infections and levels of chronic in-
flammation and increased risk of heart attack, stroke,
and cancer [32,34]. For instance, persistent peripheral
multibacteria infection, such as periodontitis, associated
with gram-negative anaerobic bacteria capable of
exhibiting localized and systemic infections in the host,
is considered as possible aggravating cofactor in subjects
with vascular diseases and risk factor for the onset of
other age-related diseases, such as AD [30].
Of special relevance is the inflammation status in cen-
tenarian people. The literature data seem to be apparently
contradictory. Increased levels of both inflammatory and
anti-inflammatory mediators and significant frequencies
of protective genotypes have been assessed in centenarians
than the old subjects [30,35]. As consequence, identifying
of apposite biomarkers likely in long lived subjects should
be necessary. This might permit a preferential and se-
lected development of pleiotropic therapeutic interven-
tions acting concomitantly on different targets and at
different levels.
Inflammatory ageing biomarkers: the crucial role of NF-κB
activators
Ageing is not a genetically programmed process, as de-
scribed above [5]. In contrast, it is recognized as an en-
tropic process, characterized by loss of molecular fidelity
and subsequent accumulation of different products [1,2].
In addition, it has been recently proposed that during
evolution the host defense and the ageing process have
become linked together [2]. Host defense and ageing
mechanisms seem to be overlapping. In particular, host
defenses seem to be involved in ageing process, to active
inflammatory network and also to evocate the release of
so-called senescence associated secretory phenotype
(SASP), represented by a myriad of factors, such as the
pro-inflammatory mediators [36,37]. A large range of
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of inflammatory network, and are all (or the major num-
ber) linked to the NF-κB pathway, an ancient signaling
pathway specialized to the host defense [25,26]. In
particular, the NF-κB system is a cytoplasmatic sensor
constituted by a protein-complex (Rel family proteins-
RelA/p65, c-Rel and RelB- and NF-κB components-
p50/p105 and p52/p100) and inhibited commonly by
binding to IκB proteins (IκBα, IκBβ, IκBγ, IκBδ, IκBε,
IκBζ and Bcl3). In some cases, its inhibition is induced
through the action of several signaling pathways and
negative feedback loops acting through different mecha-
nisms at various levels of signaling cascades. In contrast,
its activation can be evocated both by immune insults
and external and internal danger signals associated with
senescence and ageing process, such as oxidative and
genotoxic stress and tissue injuries [25]. Namely, its in-
duction is linked to several recognition pathway, i.e.
Toll-like receptors (TLRs) and inflammasome, as well as
through different upstream kinase cascades via canonical
or non-canonical pathways. IKKα/β and NIK are the
most important upstream kinases, although several ki-
nases can directly regulate the transcriptional capacity of
NF-κB factors. IKKγ, generally called NEMO, is an im-
portant regulatory component of the IKK complex being
linked upstream to genotoxic signals and IL-1 and TNF
receptor mediated signaling. Activating kinases phos-
phorylate IκB proteins which are released from the com-
plex and then degraded in proteasomes. Subsequently, the
NF-κB complexes, having the crucial role of pleiotropic
mediator of gene expression, translocate into the nucleus
and transactivate the expression of special sets of target
genes, codifying different SASP molecules, including pro-
inflammatory cytokines, chemokines, adhesion molecules,
eicosanoids, growth factors, metallo-proteinases, nitric
oxide, etc. [25]. On the other hand, emerging experimen-
tal data principally performed on human skin fibroblasts
have convincingly demonstrated the role of NF-κB signal-
ing as the major pathway stimulating SASP phenotype
[36-40]. Among the endogenous NF-κB inducers, a par-
ticular action is mediated by oxidative stress, DNA dam-
age and immune defense, which are typical features of the
entropic ageing process and age-related diseases [25].
These observations lead in considering NF-κB as hub
of ageing inflammatory network, whose the mentioned
factors act as NF-κB activators and pro-ageing factors.
With advancing age, these factors increase and deter-
mine a sustained NF-κB activation, eliciting a host
defense “catastrophe”, responsible of SASP release. In
turn, SASP, which occurs in several cells (i.e. fibroblasts,
epithelial cells, endothelial cells, astrocytes, preadipocytes,
and leukocytes as well as in postmitotic cells) participates,
together the phenomenon of inflammageing, in the low
chronic inflammation, improving both entropic ageingprocess and onset risk for age-related degenerative dis-
eases, as result of harmful responses (i.e. chronic inflam-
matory responses, increased apoptotic resistance, decline
in autophagic cleansing and tissue atrophy) (see Figure 2)
[2,36,41]. Thus, chronic inflammation predisposes individ-
uals to various age-related diseases. For example, the pro-
inflammatory SASP of senescent endothelial cells has been
proposed to contribute to CVD by initiating and fueling
the development of atherosclerotic lesions. In addition,
the expression of a SASP by astrocytes, which has been
documented both in cells that were made senescent in
culture as well as cells that were isolated from aged brain
tissue, has been suggested to initiate or contribute to
neuroinflammation, responsible of many neurodegenera-
tive diseases, such as AD, causing or exacerbating age-
related decline in both cognitive and motor function [42].
In the light of this evidence, the research has focused
the attention on identifying pro-ageing factors, “NF-κB
activators”, as possible ageing biomarkers. Here, we de-
scribe some of them as promising inflammatory bio-
markers of ageing and age-related diseases.
Oxidative stress, mitochondrial dysfunction, oxidative stress
and activation of inflammasomes
Among the ageing modifications, mitochondrial alter-
ations happen. They include an increased content of oxi-
dation products and a diminished functional activity,
conditions described and called as mitochondrial dys-
function [38,39]. An enhance of mitochondrial content
in oxidation products, accompanies the entropic ageing
process, and protein carbonyls, thiobarbituric acid reactive
substances, ROOH and 8-hydroxy-2′-deoxyguanosine are
the major markers. Recent experimental data on animal
models, such as rats and mice, demonstrate the increase
of these molecules with ageing in different tissues and or-
gans [43]. In addition, current evidence underlines the in-
crease of levels of several oxidative products in human
biofluids, such as urine, serum, plasma, and blood, from
old individuals than young subjects [44].
Mitochondrial dysfunction and oxidative stress are not
associated only with ageing process, but also with the
pathogenesis of several age-related diseases, as reported
by recent experimental literature data [45-48]. Their detri-
mental effects are commonly attributed to disturbances in
energy metabolism and increased Reactive oxygen species
(ROS) production, and the crucial role of mitochondria in
apoptotic cell death. In addition, mitochondria dysfunc-
tion and oxidative stress seem to provoke and potentiate
inflammatory responses, even if the mechanisms remain
elusive [38,39]. However, recent evidence sustains a crucial
role of mitochondria in the regulation of innate immun-
ity/inflammatory responses through different ways [49,50].
Among these, one is mediated by ROS which can induce
the assembly of multi-protein inflammatory complexes
Figure 2 NF-kB system is at the hub of aging inflammatory network Its activation is induced by different factors, such as mitochondria
dysfunction, oxidative stress, activation of Inflammasomes, decline of autophagic cleansing. Other NF-kB activators are activation of
innate/inflammatory responses by PAMPs and DAMPs, elevated induction of insulin/IGF1 pathway, acetylation and O-glycosylation of
components of NF-kB pathway, and DNA damage. NF-kB system induces entropic ageing process and release of SASP.
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Nod-like receptor protein 3 (NLRP3), a member of these
complexes and a major sensor of cellular stress signals,
such as ROS. Subsequently, NLRP3 triggers the caspase-1
mediated maturation of precursors of IL-1β and IL-18
cytokines [51,52]. Thus, an endogenous stress-related in-
flammation is activated, defined by Medzhitov as “para-
inflammation” [53]. The exact mechanism involved in
the ROS-induced NLRP3 activation is still unclear. It has
been recently demonstrated by Zhou and colleagues that
ROS could activate NLRP3 inflammasomes via the redox
regulation of thioredoxin/thioredoxin-interacting protein
balance [54]. In addition, the ROS can directly activate
the inflammasomal pathways through the oxidation of
thiol groups in leucine-rich repeat domain of NLRP3.
Furthermore, under loss of mitochondrial integrity, mito-
chondria secrete DAMPs, such as ROS, ceramide, mito-
chondrial DNA and formyl peptides, which can also
provoke activation of NLRP3 inflammasomes local and
para-inflammation responses [55,56].
Decline of autophagic function and induction of mTOR
As described above, mitochondria with disrupted integ-
rity and a deficiency in cellular housekeeping can acti-
vate through different ways NLRP3, and also NLRP1
(another member of inflammasomes) in some tissueslike brain, and stimulate inflammation [41,49,51]. In this
context, the efficient function of autophagic uptake and
lysosomal degradation of dysfunctional mitochondria
should be a crucial element in maintaining tissue
homeostasis [41]. Autophagy is, indeed, an ancient
housekeeping mechanism, which regulates cellular
homeostasis by facilitating the removal of misfolded pro-
teins and dysfunctional organelles, such as mitochondria
[57,58]. However, authophagic capacity seems to be
compromised in ageing and age-related diseases, as pro-
posed in “garbage can” hypothesis of Brunk and Terman
[55]. On the other hand, there is growing evidence on
inflammasome activation in many pathological condi-
tions. Thus, a deficiency in authophagic housekeeping
could trigger an inflammatory component and aggravate
their pathogenesis [41,49,50,56-58]. After ten years of
experimental work, the “garbage can” hypothesis still
seems to be valid, since different research approaches
have demonstrated clearly the decline of autophagy with
ageing and the increased mitochondrial dysfunction
[41,49,50,56-58]. Accordingly, the ageing decline in au-
tophagy creates problems in cellular housekeeping func-
tions, which stimulate NF-κB signaling directly or via
inflammasomes trigger SASP and provoke the onset of
entropic ageing phenotype [41]. Inflammatory NF-κB
signaling seems also to have the capacity to repress
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tween autophagy and inflammasomes [41,49,50,56-58].
In particular, TNF-α can induce or repress autophagy in
a NF-κB dependent manner. In presence of NF-κB signal-
ing, TNF-α activates mammalian Target of Rapamycin
(mTOR), a major autophagy inhibitor. On the contrary,
in cells lacking of NF-κB activation, TNF-α stimulates
the expression Beclin 1, an enhancer of autophagy
[41,49,50,56-58].
TOR is a highly conserved serine/threonine kinase and
a central controller of cell growth, metabolism and age-
ing. mTOR is activated in response to nutrients, growth
factors and cellular energy. Deregulation of mTOR has
been implicated in inflammation, ageing and several age-
related diseases (i.e. cancer, metabolic syndrome, neuro-
logical diseases) [59]. It interacts with several proteins to
form two distinct complexes named mTOR complex 1
(mTORC1) and 2 (mTORC2), differentially activated by
distinct extracellular and intracellular signals. mTORC1
responds to amino acids, stress, oxygen, energy, and
growth factors and is acutely sensitive to rapamycin. It
promotes cell growth by inducing and inhibiting ana-
bolic and catabolic processes, respectively, and also
drives cell-cycle progression. mTORC2 responds to
growth factors and regulates cell survival and metabol-
ism, as well as the cytoskeleton. mTORC2 is insensitive
to acute rapamycin treatment but chronic exposure to
the drug can disrupt its structure. The activation of
mTORC1 by growth factors and nutrients inhibits au-
tophagy and promotes protein synthesis. Over time, this
may promote cellular stress (protein aggregation, organ-
elle dysfunction, and oxidative stress), which might lead
to damage accumulation and a reduction in cell function
and thus promote the development of aging-related dis-
eases. Also, mTORC1 activation induces stem cell ex-
haustion, which reduces tissue repair and promotes
tissue dysfunction [59].
Activation of innate/inflammatory response by PAMPs and
DAMPs
During ageing, clonotypic immunity declines. This con-
dition is defined immune-senescence [30]. In contrast, in-
nate immunity seems to be efficiently activated and to
induce a chronic inflammatory phenotype, as mentioned
above [30]. The activation of innate immunity is medi-
ated through the linking of pattern recognition receptors
(PRRs), multi-ligand and evolutionarily conserved recep-
tors (i.e. TLRs, NLRs and RIG-I-like receptors), with in-
vading pathogen structures, called pathogen-associated
molecular patterns (PAMPs), and endogenous danger
molecules, the DAMPs [26]. This determines the release
of different inflammatory mediators (i.e. IL-6 and TNF-α)
by NF-κB pathway [25]. Among PRRs, TLRs, and mainly
TLR4 and TLR2, recognize not only PAMPs, but also alarge number of different alarmin age type DAMPs, in-
cluding high mobility group box 1 (HMGB1), S100, heat
shock protein (HSP)-60 and −70, and defensins [26,34]. In
addition, both TLR2 and −4 have a key role in the patho-
genesis of several age-related diseases [34]. Accordingly,
variants of genes codifying these molecules seem to mod-
ify the susceptibility of age-related diseases and survival to
extreme age, as recently described in our study [27]. On
the other hand, the +896A/G (Asp299Gly; rs4986790) and
+1196C/T (Thr399Ile; rs4986791) TLR4 SNPs have been
phenotypically associated with changes in the production
of pro- and anti-inflammatory cytokines, and principally
the Asp299Gly SNP seems to have a key role in AD,
prostate cancer, atherosclerosis and, reciprocally, in lon-
gevity [27,34].
Furthermore, an intriguing and innovative hypothesis
has been recently suggested based on the crucial role of
microRNAs in the dysfunction of TLRs signaling and the
acquisition of SASP with NF-κB activation. Thus, these
conditions can be considered as two interconnected phe-
nomena [60].
During ageing, proteins, DNA and lipids, long-live
macro-molecules can be targets of different age alter-
ations. i.e. the Maillard reaction, a well known non-
enzymatic glycosylation mechanism, induced as result of
enhance of oxidative stress and hyperglycemia [2]. This
results in the formation of protein glycation products,
called AGEs (advanced glyaction end products), consid-
ered pro-ageing factors and activating NF-κB pathway
by their linking with characteristic PRR receptors, the
RAGE receptors (receptor for advanced glycation end
products). With advancing age, AGE content increases
in tissues. AGE process also improves in diabetes, ath-
erosclerosis, neurodegeneration and several inflamma-
tory diseases. The major harmful AGE effect in ageing
seems to be the maintenance of anti-apoptotic and pro-
inflammatory phenotype. Of special note is the glycation
of collagen and elastin which seem to have a key role in
vascular pathologies [26].
Induction of NF-κB signaling pathway by pro-inflammatory
cytokines (mediated/or not by lipid rafts)
Activation of innate immunity in ageing process (see
above) determines the production and release of SASP,
such as different inflammatory molecules. Among these,
pro-inflammatory cytokines are mostly observed to be at
elevated level in elderly people. These cytokines can also
activate the NF-κB pathway and this way can propagate
and aggravate the inflammatory changes. IL-6 and TNF-
α are clearly up-regulated with ageing, even if their exact
role in the ageing process has been difficult to establish
because of their complex and cell-type functions [25].
Recent evidence reported that NF-κB pathway activa-
tion via pro-inflammatory cytokines, and particularly via
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binding of TNF-α to the TNF receptor (TNFR) results in
receptor clustering within specialized domains at the cell
surface, named as lipid rafts, which function as physical
platforms for various molecules and are involved in a
variety of biologic processes, such as molecular sorting,
membrane trafficking, and signal transduction. For ex-
ample, lipid rafts are important in the primary steps of
T-cell antigen receptor signaling and B-cell antigen re-
ceptor signaling via triggering the phosphorylation of
adaptor proteins [61]. The dynamic recruitment of
ligand-bound receptors into lipid rafts has been sug-
gested to be critical for the initiation of signaling trans-
duction, including the NF-κB pathway. Legler and
colleagues [62] reported that translocation of TNFR to
lipid rafts is essential for TNF-α-mediated NF-κB activa-
tion, and disturbances in lipid raft organization switch
the effect of TNF-α signaling from NF-κB activation to
apoptosis, demonstrating that lipid rafts are crucial for
the outcome of TNF-α-activated signaling pathways. In
addition, lipid rafts have also been demonstrated to be
required for NF-κB activation induced by IL-1, lipopoly-
saccharides, CD40L, or CD3/CD28, and the disruption
of lipid rafts results in the inhibition of NF-κB activation
mediated by these stimuli [63-65]. These studies indicate
that lipid rafts play important roles in the activation of
proximal NF-κB signaling.
Excessive stimulation of insulin/ insulin like growth factor
(IGF) signaling
An excessive insulin/IGF signaling has been demon-
strated to accompany ageing process [2]. Insulin/IGF
signaling determines detrimental age effects via NF-κB
pathway evoking activation of IκB kinase α/β complex.
As consequence improving of inflammatory responses
and resistance of apoptosis are induced. Given that
impairing the signaling of insulin/IGF signaling pathway
can activate the FOXO-dependent lifespan extension,
this implies the role of NF-κB pathway in driving the
ageing process via insulin/IGF axis [66].
Post-translation modifications of the members of NF-κB
pathway
Members of NF-κB pathway are targets of several post-
translation modifications. They influence both the activa-
tion of the pathway and transcriptional efficiency of NF-
κB system [2,25]. Phosphorylation and ubiquitination are
the major regulatory changes during activation. Acetyl-
ation, O-glycosylation and sumoylation can also control
the transcriptional efficiency of NF-κB system during
stress condition., i.e. inflammatory responses. In addition,
increased protein acetylation can also activate cellular sen-
escence. On the other hand, molecules involved in cellular
survival, such as the Sirtuin molecules (see below), andparticularly SIRT 1 and 6, can deacetylate a NF-κB com-
ponent, the p65, and repress NF-κB signaling [2,25].
Glucose tolerance decline, cause of insulin resistance
and hyperglycemic disorders, determines O-glycosylation.
Chronic hyperglycemia mediates glucotoxicity through
AGE formation or via the production of O-linked N-
acetylglucosamine (o-GlcNac)-modified proteins. On the
other hand, levels of O-glycosylated proteins increase
during ageing. In particular, an increased O- glycosyla-
tion of Ikkβ protein, able to enhance NF-κB activity, has
been observed during ageing. O-glycosylation can also
target p65 NF-κB protein and potentiate the transcrip-
tional efficiency NF-κB components. This action is reg-
ulated by p53 protein, which can inhibit glycolysis and
subsequently suppress the activation of Ikkβ/ NF-κB
signaling [2,25].
DNA damages
One of the major stochastic age mechanism is genomic
instability [2,67]. DNA lesions appear during ageing in
both nuclear and mitochondrial DNA, as result of free
radicals and oxidative stress. Under genotoxic stress, the
major pathways activated are p53, NF-κB and PARP-1
(poly-(ADP-ribose)-polymerase-1) [67]. In particular, ac-
tivation of NF-κB signaling represents one of the princi-
pal cellular features evoked by DNA damage [68]. The
DNA damage-dependent NF-κB activation cascade is de-
fined NEMO shuttle, since an essential NF-κB modula-
tor (NEMO; as mentioned above) under genotoxic stress
forms an complex with PIDD (p53-induced protein with
a death domain) and RIP1 (receptor interacting protein)
kinase [69]. This complex accumulates in nuclei and a
nuclear matrix ligase (PIASy) can sumoylate the NEMO
protein. Sumoylation is a prerequisite to allow a Ataxia
telangiectasia mutated (ATM) kinase to phopshorylate
NEMO protein. Subsequently, NEMO is desumoylated
and the NEMO/ATM complex is exported from nuclei
in cytoplasm where it activates Ikk kinases, by triggering
NF-κB signaling. This consents to prevent the p53-
induced apoptosis, since Ikk kinases phosphorylate p53
and induce its degradation by proteasomes [67-69].
Another hallmark of DNA damage is the induction of
PARP-1 pathway, an ubiquitously expressed member of
PARP family of enzymes able to modify proteins by poly
(ADP-ribosyl)lation. PARP-1 is a sensor of DNA damage
and maintains the genome integrity by regulating DNA
repair [70]. In addition, PARP-1 is considered a novel
co-activator of NF-κB signaling, which can potentiate
the NF-κB activation in genotoxic stress [25,71]. Fur-
thermore, it is one of the proteins involved in the regula-
tion of the length of nucleoprotein structures located at
the ends of chromosomes, the telomeres [71]. Telomeres
are subject to shortening at each cycle of cell division
and are highly sensitive to damage induced by oxidative
Table 2 Potential therapeutic interventions and effects
on targets of inflammatory network
Therapies Target effects
Monoclonal antibodies against these
cytokines and their receptors
Reduction of levels of
IL-6, TNF-α
Non-steroidal anti-inflammatory drug
Agonists of cytokine receptors or
PRR receptors for people who do
not respond to (or comply with)
NSAID therapy
Antibody-mediated stimulation of
the decoy TLR receptors, such as
TAM receptors, or of the intracellular
TLR regulators for people with
pro-inflammatory alleles in TLR4
and TLR2 genes
Statin therapy
Physical activity
Administration of prebiotics
and probiotics
Caloric restriction Decrease of oxidative stress
Polyphenols
Use of drugs having mimic
CR action
Caloric restriction Mitochondria biogenesis as
preventive action against
mitochondrial dysfunction
Use of drugs having mimic
CR action
Polyphenols
Caloric restriction Reduction of the activation
of NF-KB pathway
Terpenoids
Resveratrol
Use of specific miRNAs
Administration of prebiotics
and probiotics
Use of drugs having mimic CR
action Curcumin
Caloric restriction: inhibition
of mTOR pathway
Preventive action on the
possible reduced activity
of autophagic cleansing
Rapamycin: inhibition of
mTOR pathway
Curcumin: influences the
mTOR pathway
Caloric restriction Reduction of the excessive
activation of Insulin/IGF1
pathway
Metformin with CR mimic response
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oxidative stress induce increased base oxidation. In con-
trast, to the majority of genomic DNA, there is evidence
that telomeric DNA is deficient in the repair of single
strand breaks. Thus, it creates a persistent damage of
telomeres and a faster rate of telomere shortening,
which induces cellular senescence and a faster rate of
biological ageing. Since chronic oxidative stress plays a
major role in the pathophysiology of several chronic in-
flammatory diseases, it has been hypothesized that telo-
mere length is reducing at a faster rate during oxidative
stress. On the other hand, telomere shortening has been
assumed a biomarker of premature cell senescence in
vascular and metabolic diseases [71,72]. Therefore, as-
sessment of telomere length as well as the evaluation of
both function and integrity of PARP-1 might be useful
biomarkers of both biological ageing and disease onset
and progression [71,72].
Potential strategies against ageing and age-related
diseases: drug and nutrition interventions and life-style
modifications, and their effects on targets of
inflammatory network
An excessive activation of NF-κB signaling pathway
characterizes the entropic ageing process, responsible of
inflamm-ageing and SASP phenotype, and the conse-
quent onset of several age-related diseases [31-34,36].
This is plausible since nearly all insults enhancing the
ageing process are well-known activators of NF-κB sig-
naling system, as illustrated in Figure 2. The NF-κB sig-
naling pathway also represents the lynchpin of host
defense receiving the input signaling from the PRR re-
ceptors and subsequently organizing the transcriptional
output response against the acute danger [25,26]. In
both two cases, the sustained activation of NF-κB signal-
ing pathway can trigger and enhance the entropic ageing
process in many different ways, as above described [1,2].
Thus, the NF-κB system is at the hub of ageing process.
This concept leads us in considering molecules and mech-
anisms linked to NF-κB signaling system as potential age-
ing biomarkers, as described. In addition, we also suggest
them as targets for the development of new therapeutic
strategies against ageing and age-related diseases.
On the basis of data reported herein, we proposed some
suggestions on possible therapeutic drug and nutrition in-
terventions and life-style modifications, and their effects
on targets of inflammatory network (see Table 2).
Anti-inflammatory drug interventions
➢Use of monoclonal antibodies and/or non-steroidal
anti-inflammatory drugs The presence of “high-risk”
levels of IL-6 and TNF-α in elderly people suggests the
possibility to develop preventive measures using specificinhibitors, such as monoclonal antibodies against these
cytokines and their receptors. Reduction of inflamma-
tory mediators may be also induced through non-
steroidal anti-inflammatory drug (NSAID) therapy. For
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therapy, other more sophisticated preventive approaches
may be possible, including the use of agonists of cyto-
kine receptors or PRR receptors, i.e. TLR4 and −2, par-
ticularly in subjects carriers of high inflammatory
responder alleles [27,34]. On the other hand, the activa-
tion of PRR receptors, such as TLR4 and −2, evocated
by PAMPs or DAMPs particularly upon ageing, induce
the release via NF-κB pathway of a large number of
components of SASP, such as pro-inflammatory IL-6
and TNF-α cytokines [26,34]. In addition, the magnitude
of cytokine production, and in general that of all pro-
inflammatory mediators, has been shown to vary indi-
vidually and is likely based on genetic heterogeneity.
One or more functional SNPs in one or more innate
immunty genes might be responsible. Accordingly, re-
cent studies have suggested the role of +896A/G TLR4
SNP in cytokine production. In particular, high levels of
pro-inflammatory cytokines were observed in carriers
bearing the +896A/G TLR4 SNP [27,34].
Another possible therapeutic intervention in subjects
with pro-inflammatory alleles of TLR4 and TLR2 genes
might be antibody-mediated stimulation of the decoy
TLR receptors, such as TAM receptors, or the intracel-
lular TLR regulators (i.e. Supressor of cytokine
signaling-SOCS molecules), involved in the inhibition of
the inflammatory response, by mediating TLR degrad-
ation, or the activation of competitive or depho-
sphorylation functions [73]. The sequential induction of
these pathways, and their integration with upstream
TLR and cytokine signaling networks, may limit the in-
flammatory response and maintain innate immune sys-
tem homeostasis. A better understanding of the
regulatory mechanisms of this cascade may have import-
ant implications for therapeutic intervention in human
immune disorders and reduce the risk development for
several age-related diseases [27,34].
➢Statin therapy Statin therapy has been demonstrated
to have benefical effects in reducing primary and sec-
ondary CVD risk through the lipid-lowering, but also
in inducing anti-ageing actions, such as inflammatory
molecule lowering, especially IL-6 and CRP. On the
other hand, results from Justification Trial Evaluating
Rosuvastatin (JUPITER) confirmed that statin treat-
ment in apparently healthy subjects with elevated
CRP and non-elevated Low density lipoprotein choles-
terol resulted in significant reduction in both these
markers and CVD [74].
Nutrition interventions and life-style modifications
➢Caloric restriction Another possible anti-ageing strat-
egy, able to reduce the biological effects of NF-κBsignaling pathway in ageing, is the notable caloric re-
striction (CR) [75]. Restricting the intake of calories has
been practiced as a method for increasing both the
length and quality of life for over 500 years. Experimen-
tal work confirming the success of this approach in ani-
mals has accumulated over the last 100 years. CR may
extend life by up to 50% in rodents, with progressively
less impact the later in life it is started. This effect is
matched by profound impacts on age-related diseases,
including reduced risk of cancer, neurodegenerative dis-
orders, autoimmune disease, CVD and T2DM [75]. The
disposable soma theory of ageing suggests that CR
evolved as a somatic protection response to enable ani-
mals to survive periods of food shortage [4]. The shut-
down of reproductive function during CR is consistent
with this suggestion, but other features of the
phenomenon are less consistent with this theory. Some
researchers have, indeed, proposed that in rodents it
may be mostly an artifact of domestication. CR induces
profound effects on animals at all levels from the tran-
scriptome to whole animal physiology and behavior. An-
imals under CR lose weight which is disproportionately
contributed to by white adipose tissue. Generally animals
on CR change their activity patterns. Thus, they are
more active prior to food delivery each day, but total ac-
tivity may be unchanged or reduced [75]. Considerable
debate has occurred over the effects of CR on resting
metabolic rate (RMR). Total RMR declines, but as body
mass and body composition also change it is unclear
whether metabolism at the tissue level also declines, is
unchanged or even increases. Body temperature univer-
sally decreases. Hunger is increased and does not seem
to decline even with very long term restriction. Circulat-
ing adipokines are reduced reflecting the reduction in
white adipose tissue mass under CR [75]. There is also a
large reduction in circulating insulin and glucose levels.
There are profound tissue level changes in metabolism
with a generalized shift from carbohydrate to fat
metabolism.
Four pathways have been implicated in mediating the
CR effects. They are the insulin/IGF-1signaling pathway,
the Sirtuin pathway, the adenosine monophosphate
(AMP) activated protein kinase (AMPK) pathway and
mTOR pathway [75]. These different pathways may
interact and all play important roles mediating different
aspects of CR response. Exactly how they generate the
health benefits remains open for debate. However, one
of the major impact of CR is the reduction of oxidative
stress [76]. As described above, the major cellular source
of ROS are the mitochondria. Isolated mitochondria
from animals under CR show a reduced ROS produc-
tion. In particular, CR results in an increase in the level
and activation of adenine nucleotide translocase and un-
coupling proteins able to reduce the mitochondrial
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oxide radical (O2) production and a less damage to the
lipids in the mitochondrial membrane reduced ulteriorly
by increases in the membrane lipid saturation [76]. In-
creases in superoxide dismutase convert superoxide into
hydrogen peroxide and increased levels of Se-dependent
glutathione peroxidase and catalase convert this to water
reducing the production of the toxic hydroxyl radical
(OH). Lowered levels of OH diminish the oxidative dam-
age to proteins and DNA, which is further ameliorated
by enhanced levels of degradation and base excision re-
pair respectively [76]. Furthermore, CR induces mito-
chondrial biogenesis, as evidenced by changes in
mtDNA levels, and protein levels [77]. Such effects on
mitochondrial biogenesis are consistent with the idea
that there may be a tissue level increase in oxygen con-
sumption under CR which is accommodated in the re-
duced overall energy budget by the reduced amount of
metabolizing tissue.
In addition, CR increases the levels of a member of
Sirtuin family (SIRT1 to SIRT 7), NAD + dependent
deactylases involved in the regulation of the activity of
many proteins, energy metabolism, cell survival and lon-
gevity [78,79]. In particular, CR increases the expression
of SIRT1 in multiple tissues, even if this effect does not
appear to be uniform in all tissues or across different
studies [80]. It has been demonstrated that SIRT1 inter-
acts with p65/RelA protein and specifically cleaves the
acetyl group form, the lysine-310 of p65 protein, in-
volved in enhancing the trans-activation efficiency of
NF-κB system [81,82]. Thus, SIRT1 is a potent inhibitor
of NF-κB system.
An enhanced autophagy is also induced by CR via the
inhibition of mTOR or the activation of AMPK pathway.
This last is an evolutionary conserved sensor for distur-
bances in cellular energy balance and a major inductor
of autophagy. Thus, CR acts directly or indirectly as in-
hibitor of NF-κB system [75,81,82].
Based on these observations, it is possible to assume
that CR has beneficial effects, i.e. the extension of the
average and maximum life span and delaying the onset
of age-associated changes. However, this has been
proven only in animal models, such as yeast, worms,
flies and some mammals (rats and mice), and some
criticisms (as above suggested) lead to consider it as
an artifact of domestication, particularly in rodents
[75,83-85]. In higher mammals, CR delays many diseases
associated with aging including cancer, diabetes, athero-
sclerosis, CVD and neurodegenerative diseases [86,87].
The incidence of these diseases increases with age and
they contribute significantly to mortality. Therefore, CR
could increase life span by increasing the body’s general
state of health and providing a nonspecific, resistance to
chronic diseases and metabolic derangements [86,87].However, the ultimate question, how does CR effect the
human body, was studied in a limited number of experi-
ments [88]. The study of CR effects on human longevity
faces ethical and logistical challenges since the average
life span is close to 80 years for the population in devel-
oped countries. Therefore, human studies are focused
on measuring the CR-related changes that could slow
the aging process and the progression of chronic dis-
eases thus increasing life span. The most convincing evi-
dence that CR could have a positive effect in humans
was provided by experiments by Fontana and coworkers,
by the Comprehensive Assessment of Long-Term Effects
of Reducing Calorie Intake (CALERIE Phase 1), and by
data obtained on the members of the Caloric Restriction
Society [89-93].
Fontana and coworkers [89] assessed the effect of a 6-
year long CR diet on risk factors for atherosclerosis in
adult male and female adults (age range 35–82 years)
and compared them to age-matched healthy individuals
on typical American diets (control group). The total
serum cholesterol level and low-density lipoprotein
(LDL) cholesterol levels, the ratio of total cholesterol to
high-density lipoprotein cholesterol (HDL), triglycerides,
fasting glucose, fasting insulin, CRP, platelet-derived
growth factor AB, and systolic and diastolic blood pres-
sures were all markedly lower in the CR group. The
HDL cholesterol was higher after CR. Medical records of
individuals in the CR group indicated that, before they
began CR, they had serum lipid-lipoprotein and blood
pressure levels in the expected range for individuals on
typical American diets, and similar to those of the com-
parison group. Thus, this study concluded that long-
term CR can reduce the risk factors for atherosclerosis.
The effect of fat loss induced by either (a) a long-term
20% CR or (b) a 20% increased energy expenditure (IEE)
by exercise on coronary heart disease (CHD) risk factors
was detected in a one-year randomized, controlled trial
on 48 non-obese male and female subjects. The CR or
exercise induced reductions in body fat were quantita-
tively similar and were accompanied by similar reduc-
tions in most of the major CHD risk factors, including
plasma LDL-cholesterol, total cholesterol/HDL ratio,
and CRP concentrations. Thus, these data evidenced that
long-term CR or IEE of the same magnitude lead to sub-
stantial and similar improvements in the major risk fac-
tors for CHD in normal-weight and overweight middle-
aged adults [90].
The effects of a 1-year, 20% CR regime or 20% IEE by
exercise, on the oxidative damage of DNA and RNA,
was evaluated by white blood cell and urine analyses in
normal-to-overweight adults. Both interventions signifi-
cantly reduced oxidative damage to both DNA and RNA
in white blood cells compared to baseline. However,
urinary levels of DNA and RNA oxidation products did
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intervention program. The conclusion of the study was
that either CR or IEE by exercise reduce systemic oxida-
tive stress which is reflected in a decreased DNA or
RNA oxidative damage [91].
CALERIE, a research program initiated by the Na-
tional Institute on aging and involving three research
centers, performed in the Phase 1 three pilot studies to
determine whether long-term (6–12 months) effects of
20–25% CR in free-living, non-obese humans could be
investigated and to evaluate the adaptive responses to
CR. This randomized, controlled, clinical trial concluded
that CR subjects had a lower body weight, a decreased
whole body and visceral fat, a reduced activity energy ex-
penditure, improved fasting insulin levels, improvements
in cardiovascular disease markers (LDL, total cholesterol
to HDL ratio, and CRP), and no change in bone density
compared to controls [88]. In the ongoing CALERIE
Phase 2, the researchers are testing whether 2 years
sustained 25% CR of ad libitum energy intake results in
beneficial effects, similar to those observed in animal
studies [92].
Members of the Caloric Restriction Society (CRS) re-
strict food intake with the expectation that this would
delay the disease processes responsible for secondary
aging and to slow the primary aging process. Compared
to age-matched individuals eating typical American di-
ets, CRS members (average age 50 ± 10 yr) had a lower
body mass index, a reduced body fat, significantly lower
values for total serum cholesterol, LDL cholesterol, total
cholesterol/LDL, and higher HDL cholesterol. Also
fasting plasma insulin and glucose values were signifi-
cantly lower than in the age-matched control group. Left
ventricular diastolic function in CRS members was similar
to that of about 16 years younger individuals. Chronic in-
flammation was reduced by CR and this was reflected in
significantly lower levels of plasma CRP and TNF-α [88].
Aging is associated with a progressive reduction in
heart-rate-variability (HRV)—a measure of declining
autonomic function—and also a worse health outcome.
The effect of a 30% CR on heart autonomic function
was assessed by 24-hour monitoring of HRV in adults
on self-imposed CR for 3 to 15 years and compared with
an age-matched control eating a Western diet. The CR
group had a significantly lower heart rate and signifi-
cantly higher values for HRV. Also, HRV in the CR indi-
viduals was comparable to published norms for healthy
individuals 20 years younger. The authors suggest that
CR reset the balance between the sympathetic/parasym-
pathetic modulation of heart frequency in favor of the
parasympathetic drive thus increasing the circadian vari-
ability of heart rate [93].
Thus, in humans CR could delay many diseases associ-
ated with aging including cancer, diabetes, atherosclerosis,cardiovascular disease, and neurodegenerative diseases. As
an alternative to CR, several CR mimetics have been tested
on animals and humans, as described below.
➢CR mimetic drugs: biguanides, stilbenes and drugs
Considerable effort has been directed in recent years to
find drugs that mimic the CR response. Promising can-
didates are those that intersect with the critical signaling
pathways identified above and include biguanides such
as metformin, capable to target insulin signaling path-
way, stilbenes (e.g. resveratrol) affecting sirtuin activity
and drugs such as rapamycin that interact with mTOR
signaling. Whether it will ever be possible to find drugs
that capture the health benefits of CR without the nega-
tive side-effects remains unclear. Moreover, even if such
drugs are developed how the current licensing system
for drug use in western societies would cope with them
may be a further obstacle to their use [75,88,94-96].
➢Polyphenols and resveratrol (a stilbene phytochemical)
As mentioned above, several plant derived, folk medical
compounds and extracts have been claimed to have anti-
ageing effects [75,88,97-101]. However, only a small num-
ber of traditional remedies has been subjected to a clinical
trial. Recently, many promising compounds have been
identified and scrutinized. Among these, there are poly-
phenols (i.e. flavonoids and terpenoids), the major ingredi-
ents of fruits, vegetables and different spices [75,88,97-101].
Many of polyphenols are inhibitors of NF-κB signaling
system, since they are potent antioxidants, and as conse-
quence they can inhibit ROS production and activation of
NF-κB signaling system [97-101]. Some of them (i.e. terpe-
noids) can also directly inhibit Ikk/ NF-κB signaling
[97-101]. Accordingly, it has been found that low-doses of
terpenoids can trigger cellular stress response and subse-
quently induce adaptive stress resistance, condition de-
fined hormesis [97-101]. Stress resistance involves several
molecular adaptations via the activation of AMPK path-
way and the subsequent increase in the expression of sur-
vival genes, such as Sirtuins, FOXOs and p53 [97-101]. Of
special note is the effect of resveratrol, a stilbene phyto-
chemical. It induces activation of SIRT1 via AMPK path-
way, and indirectly inhibition of NF-κB signaling system
via the activation of survival genes [97-101].
➢Curcumin It has been postulated that a natural agent,
curcumin, could influence cellular senescence [102].
Curcumin has attracted the attention of researchers and
clinicians as an anti-inflammatory and anti-oxidant
agent with a potential use in the therapy of many dis-
eases with an inflammation constituent, e.g. cancer,
CVD, AD, rheumatoid arthritis and metabolic syndrome.
A plethora of studies using animal and cell line models
have been undertaken to elucidate the molecular
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some clinical trials are underway. Sikora and colleagues
[103] proposed that curcumin might act as an anti-aging
agent not only by inhibition of NF-κB, but also by
indirect influence on cellular senescence via mTOR.
However, they also showed that conversely curcumin
can induce senescence in colon cancer cells [104]. More-
over recent studies by Quitschke [105] also revealed
the prosenescence activity of curcumin. Nonetheless,
curcumin has many molecular targets and evokes a bi-
phasic hormetic dose–response [106]. Thus, one cannot
exclude that much lower concentration of curcumin
than that used in these studies will inhibit/postpone cel-
lular senescence or, at least, through NF-kB inhibition
will reduce SASP. Interestingly, curcumin was shown to
prolong life of model organisms such as Caenorhabditis
elegans and Drosophila melanogaster, but did not influ-
ence (similarly to resveratrol) the life span of mice [107].
➢Physical activity Promising evidence suggests a role
of physical activity in reducing the levels of inflamma-
tory markers. Several speculations have been advanced
[108-111]. However, the mechanisms underlying its anti-
inflammatory effects seem complex and not fully eluci-
dated. It has been recently considered that the decreased
production of proinflammatory cytokines may originate
from a reduction of adiposity, or the release of muscle
derived IL-6 [108-111]. This last seems to induce several
metabolic adaptations, i.e. hepatic glycogenolysis and lip-
olysis, and the release of cytokine inhibitors (i.e. IL-1ra,
sTNFR and IL-10) and cytokine with potent anabolic ef-
fect, as IL-15 [108-111].
➢Probiotics and/or prebiotics Administration of
probiotics and/or prebiotics to elderly seems to induce
changes in several inflammatory parameters (i.e. pro-
inflammatory cytokine lowering, CRP reduction), demon-
strating that manipulation of gut microbiota may result in
modification of functionality of an aged immune system.
On the other hand, intestinal microbiota seems to play a
fundamental role in maintaining human health. Its sup-
posed importance in human physiology has recently led to
label human subjects as “metaorganisms” because of their
close symbiotic relation with indigenous gut microbiota.
The “metaorganisms” hypothesis evidences the use of diet-
ary supplementation with probiotics and prebiotics, as
therapeutic strategy to preserve human health particularly
during that life period not foreseen by evolution- “ageing”-,
that inexorably alters gut microbiota composition, stability
and functionality [112,113].
Conclusions
From all observations described above, chronic inflam-
mation has been proposed as the major biologicalmechanism underpinning the entropic ageing process
and age-related diseases [31-34,36]. Inflammation is also
the key response of host defense against pathogens and
tissue injury [25,26]. In addition, it is current opinion
that during evolution the host defense and ageing
process have become linked together [2]. Thus, the large
array of defense factors and mechanisms linked to the
NF-κB system seem to be involved in the entropic age-
ing process [2,25]. This concept leads us in proposing
inductors of NF-κB signaling system as potential ageing
biomarkers and promising targets for the development
of new therapeutic strategies against ageing and age-
related diseases. In this report, we describe some inflam-
matory mechanisms linked to NF-κB signaling system as
potential ageing biomarkers. In addition, some sugges-
tions on their role as promising targets for the develop-
ment of new therapeutic strategies have been discussed.
Our interest has been, particularly, focused on possible
interventions on molecular survival and resistance stress
pathways, capable to reduce or inhibit NF-κB signaling
pathway. However, it is not impossible to predict,
whether these possible interventions (appropriate and
specific drug therapies, lifestyle modifications, use of CR
mimetics and other preventive therapeutic strategies)
can very reduce or retard the onset of ageing biological
phenotype and the onset risk of age-related diseases. Dif-
ferent motivations lead us to have prudence. Firstly, the
major literature data on anti-ageing effects of thera-
peutic strategies have been obtained from studies on ani-
mals. Thus, potential therapy interventions on the basis
of pathways identified in model organisms may be an
illusion, because gains in longevity achieved in these or-
ganisms seem to decline with organismal complexity or
depend on idiosyncratic physiology. Furthermore, life-
span in some organisms may be less plastic than in
others. In addition, there are still enormous gaps in our
knowledge about how metabolic pathways operate and
interact. Serious side effects may constrain the effective-
ness of pharmacological interventions.
The best treatment might be that which consents the
repair of macromolecular damage. However, it is not
clear that all toxic lesions associated with ageing process
have been identified, or whether practical and appropri-
ated strategies exist to eliminate them, as those men-
tioned above. Today, the researchers are becoming to
speculate the concept based on reprogramming cellular
senescence as way of organism rejuvenation or at least
to alleviate age-related diseases considering cellular sen-
escence as target model [114-116]. This hope derives by
results of recent studies on progeroid mice demonstrat-
ing the possibility to reverse progeroid phenotype
through genetic manipulation. This intervention of
avoiding or reversing cellular senescence is based on in-
duced pluripotent stem cell technology, which opened a
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possibility to activate telomerase and change the telo-
mere length [117,118]. Accordingly, other studies are
needed to confirm and extend these current data. For
example, genomic, transcriptomic and epigenetic investi-
gations may eventually lead to better understanding the
molecular and cellular inflammatory mechanisms associ-
ated with biological ageing. In addition, for the develop-
ment of anti-ageing therapies for human, it should be
more appropriate identifying cellular and serum ageing
biomarkers and potential targets using apposite study
model, such as centenarian offspring, healthy elderly
people with a family history of longevity, as recently sug-
gested [119]. On the other hand, the research of
biomarkers of ageing and age-related diseases in under-
standing the health trajectories of the oldest-old is unex-
plored territory. It is important that this lacuna is filled
given the rapid growth in the number of very old people
in many contemporary populations. The goal of this re-
search might guarantee improving of life quality rather
than searching the elixir of long life.
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